G&E Herbal Biotechnology Co., Ltd.
G&E Herbal Biotechnology Co., Ltd. engages in development and commercialization of novel botanical extraction technology and products in Taiwan. It offers Hepanamin capsules; botanical food supplements; botanical anti-aging cosmetics, such as facial cleansing essence, botanic extract toner, moisturizing cream and serum, and essential oil; smile cream and topical gel; as well as adult products, in… Read more
G&E Herbal Biotechnology Co., Ltd. (4911) - Net Assets
Latest net assets as of September 2025: NT$900.74 Million TWD
Based on the latest financial reports, G&E Herbal Biotechnology Co., Ltd. (4911) has net assets worth NT$900.74 Million TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$967.19 Million) and total liabilities (NT$66.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$900.74 Million |
| % of Total Assets | 93.13% |
| Annual Growth Rate | 6.84% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.16 |
G&E Herbal Biotechnology Co., Ltd. - Net Assets Trend (2021–2024)
This chart illustrates how G&E Herbal Biotechnology Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for G&E Herbal Biotechnology Co., Ltd. (2021–2024)
The table below shows the annual net assets of G&E Herbal Biotechnology Co., Ltd. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$833.53 Million | +9.21% |
| 2023-12-31 | NT$763.24 Million | +10.48% |
| 2022-12-31 | NT$690.84 Million | +1.08% |
| 2021-12-31 | NT$683.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to G&E Herbal Biotechnology Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 24990500000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$102.06 Million | 12.24% |
| Other Components | NT$731.47 Million | 87.76% |
| Total Equity | NT$833.53 Million | 100.00% |
G&E Herbal Biotechnology Co., Ltd. Competitors by Market Cap
The table below lists competitors of G&E Herbal Biotechnology Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SNS
KLSE:0259
|
$49.71 Million |
|
Gateway Mining Ltd
AU:GML
|
$49.71 Million |
|
Golden Biotechnology Corporation
TWO:4132
|
$49.73 Million |
|
CCK Consolidated Holdings Bhd
KLSE:7035
|
$49.73 Million |
|
Amicogen Inc
KQ:092040
|
$49.68 Million |
|
NCL Industries Limited
NSE:NCLIND
|
$49.68 Million |
|
Clarke Inc
PINK:CLKFF
|
$49.67 Million |
|
T.K.S. Technologies Public Company Limited
BK:TKS
|
$49.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in G&E Herbal Biotechnology Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 763,235,000 to 833,534,000, a change of 70,299,000 (9.2%).
- Net income of 102,063,000 contributed positively to equity growth.
- Dividend payments of 31,764,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$102.06 Million | +12.24% |
| Dividends Paid | NT$31.76 Million | -3.81% |
| Total Change | NT$- | 9.21% |
Book Value vs Market Value Analysis
This analysis compares G&E Herbal Biotechnology Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.64x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.22x to 2.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$10.73 | NT$34.55 | x |
| 2022-12-31 | NT$10.84 | NT$34.55 | x |
| 2023-12-31 | NT$11.98 | NT$34.55 | x |
| 2024-12-31 | NT$13.08 | NT$34.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently G&E Herbal Biotechnology Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.24%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 40.98%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.15x
- Recent ROE (12.24%) is above the historical average (4.97%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -2.91% | -80.92% | 0.04x | 1.01x | NT$-88.23 Million |
| 2022 | 1.07% | 11.42% | 0.08x | 1.13x | NT$-61.70 Million |
| 2023 | 9.49% | 39.90% | 0.21x | 1.16x | NT$-3.92 Million |
| 2024 | 12.24% | 40.98% | 0.26x | 1.15x | NT$18.71 Million |
Industry Comparison
This section compares G&E Herbal Biotechnology Co., Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,107,525,400
- Average return on equity (ROE) among peers: 2.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| G&E Herbal Biotechnology Co., Ltd. (4911) | NT$900.74 Million | -2.91% | 0.07x | $49.69 Million |
| Synbio Tech Inc. (1295) | $942.97 Million | 12.01% | 1.00x | $21.72K |
| Apex Biotechnology Corp (1733) | $842.42 Million | 19.18% | 0.14x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $875.36 Million | 7.09% | 0.89x | $129.07 Million |
| Panion & BF Biotech Inc (1760) | $278.86 Million | -14.55% | 2.31x | $123.88 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $2.02 Billion | 5.81% | 0.71x | $42.95 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.16 Billion | 13.75% | 0.60x | $45.13 Million |
| Level Biotechnology (3118) | $498.78 Million | 7.80% | 0.36x | $22.63 Million |
| GenMont Biotech Inc (3164) | $861.62 Million | 3.30% | 0.66x | $31.27 Million |
| Medigen Biotechnology (3176) | $3.18 Billion | -14.68% | 0.53x | $100.57 Million |
| Sagittarius Life Science (3205) | $419.76 Million | -11.56% | 0.24x | $56.40 Million |